P
Protalix BioTherapeutics, Inc. (PLX)
ASE – Real Time Price. Currency in USD
1.91
-0.03 (-1.55%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
1.91
-0.03 (-1.55%)
At close: May 12, 2026, 4:00 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.51 | 6.05 | 10 | |
| Quick ratio | 1.54 | 5.63 | 8.0 | |
| Debt to Equity | 0.17 | 0.30 | 9.0 | |
| Debt to Assets | 0.10 | 1.04 | 9.0 | |
| Interest coverage | -12.16 | -16.91 | 1.0 | |
| Weighted average score | 7.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 48M | 65M | 53M | 53M | 53M |
| Gross Profit | 28M | 43M | 29M | 25M | 26M |
| Operating Income | -13M | 10M | 4M | -6M | -6M |
| Net Income | -15M | 8M | 3M | -7M | -7M |
| EBITDA | -12M | 12M | 5M | -4M | -4M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 13.72 | 80 | 9.0 |
| Next quarter | 141.41 | N/A | 5.5 |
| Current year | 49.87 | 368.75 | 10 |
| Next year | -12.65 | -67.44 | 1.0 |
| Weighted average score | 6.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -48.89 | -333.71 | -299.99 | 138.46 | 3.3 |
| Y/Y | -49.92 | -184.75 | -159.99 | -54.36 | 1.0 |
| 3y average | 5.93 | -78.08 | -75.49 | 68.54 | 4.3 |
| 5y average | 0.6 | -102.23 | -71.65 | 28.71 | 3.5 |
| Weighted average score | 3.0 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $15.4M significantly exceed its total debt $8.3M, ensuring strong financial flexibility
Total current assets $66.7M exceed Total current liabilities $26.5M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-12.2x) is dangerously low, suggesting debt repayment risks
The company generates positive free cash flow $1.6M, supporting its financial health